Omnipaque and Urografin in left ventriculography and coronary arteriography. A randomised, double blind study.
In order to compare tolerability and radiographic properties of Omnipaque (iohexol) 350 mg I/ml and Urografin (sodium meglumine diatrizoate) 76% (370 mg I/ml) in left ventriculography and coronary arteriography, a randomised, double-blind parallel study was conducted. ECG, heart rate, blood pressure, cardiac output, oxygen saturation, CK-MB, adverse reactions and opacification were recorded. Twenty-five patients received Omnipaque and 24 Urografin and all patients were included in the final material. Omnipaque was found to have less influence on haemodynamics than Urografin. Few adverse reactions were encountered in the entire study, but fewer after injections of Omnipaque than after Urografin. Equally good opacification was demonstrated for both media. Omnipaque was found well suited for cardioangiography and superior to standard ionic media.
D000328:Adult; D001794:Blood Pressure / Q000187:drug effects; D002986:Clinical Trials as Topic; D017023:Coronary Angiography; D003973:Diatrizoate / Q000031:analogs & derivatives; D003974:Diatrizoate Meglumine / Q000494:pharmacology; D004311:Double-Blind Method; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006352:Heart Ventricles / Q000000981:diagnostic imaging* / Q000187:drug effects; D006801:Humans; D007463:Iodobenzoates / Q000494:pharmacology; D007472:Iohexol; D008297:Male; D008875:Middle Aged; D011897:Random Allocation; D014283:Triiodobenzoic Acids / Q000494:pharmacology
D007463:Iodobenzoates; D014283:Triiodobenzoic Acids; D003973:Diatrizoate; D003974:Diatrizoate Meglumine; D007472:Iohexol